首页> 外文期刊>Journal of clinical apheresis. >Tailored strategy for AML patients receiving allogeneic peripheral blood stem cell transplantation.
【24h】

Tailored strategy for AML patients receiving allogeneic peripheral blood stem cell transplantation.

机译:针对接受异基因外周血干细胞移植的AML患者的量身定制策略。

获取原文
获取原文并翻译 | 示例
       

摘要

Considering the heterogeneity of acute myelogenous leukemia (AML), along with the pros and cons of allogeneic peripheral blood stem cell transplantation (PBSCT), a tailored strategy is needed to minimize the transplant-related mortality and maximize the transplant outcomes in AML patients exhibiting certain factors that have an impact on the post-transplant quality of life and outcomes. The factors that need to be considered when tailoring a strategy in an allogeneic PBSCT setting include the recipient's performance status and co-morbid disease include AML risk stratification, disease status, expected severity of graft-versus-host disease, and the necessity of a graft-versus-leukemia effect. Accordingly, this review article describes a possible tailoring strategy for AML patients receiving allogeneic PBSCT based on certain factors influencing the transplant outcome.
机译:考虑到急性骨髓性白血病(AML)的异质性,以及同种异体外周血干细胞移植(PBSCT)的优缺点,需要采取量身定制的策略,以最大程度地减少与移植相关的死亡率,并最大程度地提高表现出某些特征的AML患者的移植结局影响移植后生活质量和结果的因素。在同种异体PBSCT环境中制定策略时需要考虑的因素包括接受者的表现状态和合并症,包括AML风险分层,疾病状态,预期的移植物抗宿主病严重性以及移植的必要性对白血病的作用。因此,本文将根据影响移植结果的某些因素,为接受同种异体PBSCT的AML患者描述一种可能的定制策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号